Analyzing RenovoRx (NASDAQ:RNXT) & MetaVia (NASDAQ:MTVA)

MetaVia (NASDAQ:MTVA) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Risk and Volatility

MetaVia has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Profitability

This table compares MetaVia and RenovoRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-229.48%	-105.28%
RenovoRx	-1,196.66%	-122.19%	-90.69%

Insider and Institutional Ownership

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 9.1% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MetaVia and RenovoRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1	0	2	0	2.33
RenovoRx	1	0	2	1	2.75

MetaVia currently has a consensus price target of $36.50, indicating a potential upside of 2,239.74%. RenovoRx has a consensus price target of $8.00, indicating a potential upside of 750.61%. Given MetaVia’s higher probable upside, analysts clearly believe MetaVia is more favorable than RenovoRx.

Earnings and Valuation

This table compares MetaVia and RenovoRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$27.59 million	($8.36)	-0.19
RenovoRx	$40,000.00	861.73	-$8.81 million	($0.36)	-2.61

RenovoRx has higher revenue and earnings than MetaVia. RenovoRx is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Summary

RenovoRx beats MetaVia on 10 of the 13 factors compared between the two stocks.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.